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Although Pharmaceutical health industry subject to the vague growth of the
economic and the low growth rate of environmental impact, the industry makes
full use of its own inherent resistance to the economic cyclical risks of power.
Along with an increasing enhancement of population and human consciousness
of self health care, the industry still maintain a steady growth in global
pharmaceutical market and health industry has become the most promising
sunrise industry. During the period of “13 Five-Year" project, China will promote
the healthy construction, deepening medical and health system reform,
rationalizing drug prices and the implementation of health care, medical linkage
and establishing the basic medical and health system covering urban and rural
areas and the modern hospital management system.With the improvement of
people's living standard, people pay more attention to health care and medical
health in China will better help the pharmaceutical industry transformation to meet
the people's needs. At the same time, population aging and the aging of the sick
rate is higher, the government continue to regulate the pharmaceutical industry
and increase and guide capital investment, under these factors the
pharmaceutical industry become one of China's fastest growing industry over the
years.
As a member of the pharmaceutical industry, Yunnan Baiyao Group Co., Ltd.
(hereinafter referred to as "Yunnan Baiyao") is under the strategy of the "new
Baiyao, a large health” and work as a guide, focus on personal health demand,
grasp the rule of no disease for the orientation of the future market opportunities,
which is committed to create medicine of the whole industry chain, business
covers resources of traditional Chinese medicine, western medicine materials,
preparation, personal care products, native herbs, commercial circulation. The













one of the fastest growing segments of the market, and the market development
space is broad.
This paper chooses Yunnan Baiyao as the research object, citing Harvard
Analysis Framework of Yunnan Baiyao industry background and development
strategy analysis. In combination with the company’s financial statements from
2010 to 2014 years and related data to project accounting policy and make
analysis and evaluation on the basis, from the cash flow, profit ability, operation
ability, debt paying ability and the ability to grow dimensions of Yunnan Baiyao of
financial analysis, and finally a comprehensive strategy, accounting and financial
aspects of analysis results, the prospects of the development of Yunnan Baiyao
estimate, pointing out the strategic measures of shortages and gives the
corresponding risk response and suggestions on how to solve problems. This
paper hopes to support the long-term development of Yunnan Baiyao,  also hope
that other enterprises can learn from it .
In this paper, we study that Yunnan Baiyao subdivision market is full of
opportunities for development, the company's development strategy is also clear
and pragmatic, but in the process of implementation of the strategy emphasis on
short-term seeking scale and ignore the long-term development of the company's
sustainability. It is suggested that the company make appropriate adjustments in
time to avoid the future development of stagnant or even reverse the risk.
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